121899-80-7

Upstream product

• 401-78-5 3-bromo-1-trifluoromethylbenzene 

Downstream Products

• 147378-74-3 1-(3-(trifluoromethyl)phenyl)piperidin-4-one 
• 98-08-8 α,α,α-trifluorotoluene 
• 5957-84-6 2-(3-trifluoromethylphenyl)pyridine 
• 5957-99-3 3-<3-(trifluoromethyl)phenyl>pyridine 
• 682786-14-7 N-phenyl-3-(trifluoromethyl)benzenesulfonamide 
• 1632196-80-5 C₁₇H₁₂F₃NO₂ 
• 1297610-96-8 1-(3-trifluorophenyl)-3,4-dihydronaphthalene-2-carbaldehyde 
• 1868-00-4 3,3'-bis(trifluoromethyl)benzophenone 
• 1258973-73-7 tris-(3-trifluormethylbiphenyl)amine 
• 1183410-78-7 C₁₆H₁₃F₃O 
• 580-82-5 3,3'-bis(trifluoromethyl)biphenyl 

Relevant academic research and scientific papers

Synthesis of highly functionalized triarylbismuthines by functional group manipulation and use in palladium- and copper-catalyzed arylation reactions

Organobismuthines are an attractive class of organometallic reagents that can be accessed from inexpensive and nontoxic bismuth salts. Triarylbismuthines are particularly interesting due to their air and moisture stability and high functional group tolerance. We report herein a detailed study on the preparation of highly functionalized triarylbismuth reagents by triple functional group manipulation and their use in palladium- and copper-catalyzed C-, N-, and O-arylation reactions.

Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists

Pharmacologically active benzimidazolone derivatives as 5-HT1Aand 5-HT2 receptors, useful in the treatment of CNS disorders of formula: wherein, R1 and R2 may be at the same time or not a hydrogen atom, halogen, trifluoromethyl, C1 6 alkyl, C1 6 alkoxy, C1 6 alkylthio, C1 6 acyl, carboxyl, C1 6 alkoxy- carbonyl, hydroxy, nitro, amino optionally C1 4 alkyl N-mono or di-substituted, C1 6 acylamino, C1 6 alkoxycarbonylamino, carbamoyl optionally C1 4 alkyl N-mono or di-substituted, cyano, C1 6 alkylsulphinyl, C1 6 alkylsulphonyl, amino sulphonyl optionally C1 4 alkyl N-mono or di-substituted, C1 4 alkyl N-mono or di-substituted aminosulphonylamino, aminosulphonylamino;, R3 is hydrogen, C1 6 alkyl, C2 6 alkenyl or C2-C6 alkynyl;, A is -CO- or -CONH- or it is absent;, B is a straight or branched, saturated or unsaturated C2 6 alkyl;, m and n are both independently an integer from 1 to 3;, R4 is an aryl, aralkyl, a heteroaryl or heteroaralkyl group, each group being optionally substituted by one or more substituents selected from halogen, trifluoromethyl, cyano, C1 3 alkoxy, C1 4 alkyland acid addition salts thereof., The process for the preparation of the compounds of formula I as well as pharmaceutical compositions containing them are also described.